Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With <i>NPM1</i> and <i>FLT3</i> MutationsNigel H. Russell, Shankara Paneesha, Richard Dillon et al.|Journal of Clinical Oncology|2024Cited by 40
Optimizing the management of patients with spinal myeloma diseaseSean Molloy, Maggie Lai, Guy Pratt et al.|British Journal of Haematology|2015Cited by 32